DS
SPRY icon

DRW Securities’s ARS Pharmaceuticals SPRY Stock Holding History

DRW Securities’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$351K Buy
+43,665
New +$418K ﹤0.01% 810
2025
Q4 		– Sell
-35,742
Closed -$349K – 1669
2025
Q3 		$349K Buy
+35,742
New +$513K 0.01% 779

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DRW Securities's SPRY Position: Q1 2026 in Review

DRW Securities opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 43,665 shares worth $351K. The stake represents ﹤0.01% of the portfolio and ranks #810 among its holdings. This is a return to the name: DRW Securities previously reported a position in SPRY as recently as Q3 2025.

DRW Securities first reported a position in SPRY in Q3 2025 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • DRW Securities held 43,665 shares of ARS Pharmaceuticals worth $351K as of Q1 2026.
  • ARS Pharmaceuticals was a new DRW Securities position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #810 holding.
  • DRW Securities first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.